Table II:

Changes in Pharmacokinetic Parameters (Expressed as Ratios of Interaction / Control) in Oral Drug-Drug Interaction Studies that Affect Intestinal Xenobiotic Transporters

Victim Drug:	Perpetrator Drug:	Major Enzyme or Transporter	Population	$\frac{{\mathit{M}\mathit{A}\mathit{T}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{M}\mathit{A}\mathit{T}}^{\mathit{C}\mathit{o}\mathit{n}}}$	$\frac{{\mathit{t}}_{\mathit{m}\mathit{a}\mathit{x}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{t}}_{\mathit{m}\mathit{a}\mathit{x}}^{\mathit{C}\mathit{o}\mathit{n}}}$	$\frac{{\mathit{A}\mathit{U}\mathit{C}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{A}\mathit{U}\mathit{C}}^{\mathit{C}\mathit{o}\mathit{n}}}$	$\frac{{\mathit{C}\mathit{L}/\mathit{F}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{C}\mathit{L}/\mathit{F}}^{\mathit{C}\mathit{o}\mathit{n}}}$	$\frac{{{\mathit{V}}_{\mathit{s}\mathit{s}}/\mathit{F}}^{\mathit{D}\mathit{D}\mathit{I}}}{{{\mathit{V}}_{\mathit{s}\mathit{s}}/\mathit{F}}^{\mathit{C}\mathit{o}\mathit{n}}}$	$\frac{{\mathit{M}\mathit{R}\mathit{T}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{M}\mathit{R}\mathit{T}}^{\mathit{C}\mathit{o}\mathit{n}}}$	$\frac{{\mathit{t}}_{1/2,\mathit{z}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{t}}_{1/2,\mathit{z}}^{\mathit{C}\mathit{o}\mathit{n}}}$	Percent AUC Extrapolation (DDI/Con)	Reference
Rosuvastatin (Single Dose)	Rifampin (Single Dose)	BCRP (Inhibition)	Whites (n=7)	0.47	0.50	3.37	0.28	0.082	0.30a	0.64	1%/8%	(21)
Rosuvastatin (Single Dose)	Rifampin (Single Dose)	BCRP (Inhibition)	Asians (n=8)	0.34	0.55	3.21	0.31	0.11	0.34a	0.59	1%/7%	(21)
Talinolol (Multiple Dose)	Rifampin (Multiple Dose)	P-gp (Induction)	Healthy Men (n=8)	1.70b	1.35	0.65	1.54	1.24c	0.79c	0.85	n/a (steady-state)	(22)

Pharmacokinetic values reported in the table are based on published average values, unless otherwise noted

Abbreviations: AUC, area under the curve; BCRP, breast cancer resistance protein; Con, control; CL/F, apparent clearance; DDI, drug-drug interaction; MAT, mean absorption time; MRT, mean residence time; n/a, not applicable; P-gp, P-glycoprotein; t_max, time to maximal concentration; t_1/2,z, terminal half-life; V_ss/F, apparent volume of distribution at steady state

^aMRT was calculated using Equation 7 and average reported values of CL/F and V_ss/F

^bMAT was calculated by utilization of the steady-state relationship between reported t_max and t_1/2,z (Equation 4)

^cRatios are calculated by digitization of published average plasma concentration-time profiles and performing compartmental analysis, where steady-state MRT was calculated using Eq 6